Pfizer Inc. (NYSE:PFE) Stock Position Reduced by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its position in Pfizer Inc. (NYSE:PFE) by 27.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 617,302 shares of the biopharmaceutical company’s stock after selling 229,280 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Pfizer were worth $16,369,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Brooktree Capital Management lifted its position in shares of Pfizer by 1.2% in the 4th quarter. Brooktree Capital Management now owns 115,383 shares of the biopharmaceutical company’s stock worth $3,061,000 after buying an additional 1,389 shares during the last quarter. PDS Planning Inc lifted its holdings in Pfizer by 4.0% in the fourth quarter. PDS Planning Inc now owns 32,708 shares of the biopharmaceutical company’s stock worth $868,000 after acquiring an additional 1,262 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its stake in Pfizer by 3.3% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 24,695 shares of the biopharmaceutical company’s stock valued at $655,000 after acquiring an additional 779 shares during the period. Mystic Asset Management Inc. grew its holdings in shares of Pfizer by 126.6% during the fourth quarter. Mystic Asset Management Inc. now owns 174,006 shares of the biopharmaceutical company’s stock valued at $4,616,000 after purchasing an additional 97,231 shares during the last quarter. Finally, Leelyn Smith LLC raised its position in shares of Pfizer by 6.4% during the 4th quarter. Leelyn Smith LLC now owns 87,767 shares of the biopharmaceutical company’s stock worth $2,328,000 after purchasing an additional 5,311 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $26.20 on Friday. The company has a 50-day moving average of $26.17 and a 200-day moving average of $27.05. The firm has a market cap of $148.61 billion, a price-to-earnings ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.